Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MALVERN, PA., AUG. 05, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE BOARD OF DIRECTORS OF TELA BIO APPROVED INDUCEMENT GRANTS OF STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 2,370,000 SHARES OF ITS COMMON STOCK AND RESTRICTED STOCK UNITS COVERING 500,000 SHARES OF ITS COMMON STOCK TO THE COMPANY'S NEWLY-HIRED CHIEF EXECUTIVE OFFICER, HEATHER GETZ, WITH A GRANT DATE OF AUGUST 3, 2026 (THE "GETZ GRANT DATE"). THE STOCK OPTIONS CONSIST OF (I) STOCK OPTIONS TO PURCHASE 1,365,000 SHARES OF COMMON STOCK (THE STANDARD OPTIONS) AND (II) PREMIUM-PRICED STOCK OPTIONS TO PURCHASE 1,005,000 SHARES OF COMMON STOCK (THE PREMIUM-OPTIONS). ADDITIONALLY, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF TELA BIO APPROVED INDUCEMENT GRANTS OF RESTRICTED STOCK UNITS COVERING 95,500 SHARES OF ITS COMMON STOCK TO 11 NEWLY-HIRED EMPLOYEES, WITH A GRANT DATE OF AUGUST 4, 2026. THE STOCK OPTIONS AND THE RESTRICTED STOCK UNITS DISCUSSED ABOVE WERE GRANTED PURSUANT TO THE NASDAQ RULE 5635(C)(4) INDUCEMENT GRANT EXCEPTION AS A COMPONENT OF MS. GETZ'S AND EACH INDIVIDUAL'S EMPLOYMENT COMPENSATION AND WERE GRANTED AS AN INDUCEMENT MATERIAL TO HIS OR HER ACCEPTANCE OF EMPLOYMENT WITH TELA BIO.

TELA BIO ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

MALVERN, PA., AUG. 04, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. (TELA BIO OR THE COMPANY), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, ANNOUNCED THAT THE BOARD OF DIRECTORS (THE BOARD) HAS APPOINTED HEATHER GETZ AS CHIEF EXECUTIVE OFFICER AND DIRECTOR, EFFECTIVE TODAY.

TELA BIO ANNOUNCES APPOINTMENT OF HEATHER GETZ AS CHIEF EXECUTIVE OFFICER AND DIRECTOR

MALVERN, PA., JULY 29, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE CANACCORD GENUITY 46TH ANNUAL GROWTH CONFERENCE.

TELA BIO TO PARTICIPATE IN THE CANACCORD GENUITY 46TH ANNUAL GROWTH CONFERENCE

MALVERN, PA., JULY 20, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON MONDAY, AUGUST 10, 2026.

TELA BIO TO ANNOUNCE SECOND QUARTER 2026 FINANCIAL RESULTS

MALVERN, PA., MAY 12, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. (TELA BIO), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

TELA BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

MALVERN, PA., MAY 07, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF TELA BIO APPROVED INDUCEMENT GRANTS OF RESTRICTED STOCK UNITS COVERING 89,250 SHARES OF ITS COMMON STOCK TO 12 NEWLY-HIRED EMPLOYEES, WITH A GRANT DATE OF MAY 5, 2026 (THE "GRANT DATE").

MALVERN, PA., APRIL 30, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. (TELA BIO), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED A COMPREHENSIVE BOARD REFRESHMENT PLAN DESIGNED TO SUPPORT THE COMPANY'S NEXT PHASE OF COMMERCIAL GROWTH AND OPERATIONAL EXCELLENCE.

TELA BIO ANNOUNCES STRATEGIC BOARD REFRESHMENT WITH FOUR HIGHLY EXPERIENCED COMMERICAL LEADERS TO ACCELERATE GROWTH AND DRIVE PATH TO PROFITABILITY; THE COMPANY ALSO REPORTS PRELIMINARY FIRST QUARTER 2026 REVENUES

MALVERN, PA., APRIL 21, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON TUESDAY, MAY 12, 2026. TELA BIO'S MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST AT 4:30 P.M. ET THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

TELA BIO TO ANNOUNCE FIRST QUARTER 2026 FINANCIAL RESULTS

MALVERN, PA., MARCH 24, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO"), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025.

TELA BIO REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

MALVERN, PA., MARCH 10, 2026 (GLOBE NEWSWIRE) -- TELA BIO, INC. ("TELA BIO") (NASDAQ: TELA), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY FOCUSED ON PROVIDING INNOVATIVE SOFT-TISSUE RECONSTRUCTION SOLUTIONS, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON TUESDAY, MARCH 24, 2026. TELA BIO'S MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST AT 4:30 P.M. ET THAT DAY TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

TELA Bio, Inc.

TELA

Price

Financial Reports

No items found.

Press Releases

TELA Bio, Inc.

TELA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TELA